All-electric PX injection moulding machines from KraussMaffei equipped with LRX linear robots in production at MGS in Richfield

A.i.r. Platform™ (Auto-injector reimagined) from MGS

MGS and KraussMaffei: Scaling medical production worldwide

HIGH-VOLUME medical projects for global healthcare markets demand speed, repeatability and absolute confidence in every part produced. MGS, headquartered Wisconsin, USA, provides the full value chain – from the first drawing to the packaged component – leveraging the injection moulding machinery expertise of KraussMaffei. Rapid growth dynamics often emerge when multiple all-electric PX injection moulding machines are required simultaneously.

CDMO (Contract Development and Manufacturing Organisation) defines MGS value proposition. From development to finished products, every project must run flawlessly because in pharma, diagnostics, and medtech it ultimately comes down to patient health. Dirk Paulmann, Vice President of Global Marketing of MGS, puts it this way: “We’re in the Champions League when it comes to volume, precision, and quality. To achieve this, we need the right partners.”

A global service network that builds confidence
To meet these high standards, MGS has counted on KraussMaffei machines for many years. A cornerstone is the all-electric PX with LRX linear robots in its medical configuration featuring, among other options, automatic centralised lubrication in a closed circuit. The platform is ideally suited for ISO Class 8 cleanroom manufacturing, which MGS operates with approximately 1,500 employees across sites in the US, Costa Rica, Mexico, Ireland, Sweden, Germany, Belgium, Denmark, and Slovakia.

Consistency across every cavity matters
Many MGS programs run multi-cavity moulds at demanding cycle times, making repeatability across every cavity essential. For low part weights, such as those of laboratory materials, not only is precise hot runner technology required, but also machines that guarantee a completely constant shot weight. KraussMaffei’s APCplus function offers the ideal digital solution for this. It optimally adjusts the switching point and holding pressure from shot to shot to match the respective melt viscosity.

Future growth driver: A.i.r. Platform™

One innovation poised to drive growth is the proprietary A.i.r. Platform™ (Auto-injector reimagined). Built around a fully certified internal mechanism, the platform gives MGS customers access to a proven, ready-to-use system, while allowing the external design and user interface to be customised to brand, therapy and patient needs. The result is shorter development timelines, lower technical risk, and a more efficient path through regulatory requirements toward market launch.

To support the increasing demand for this product, MGS needs a long-standing partner like KraussMaffei, which Dirk Paulmann particularly values for “the high level of attention and support we receive”, that provides a strong foundation for the future partnership.

• KraussMaffei is represented by Plastic & Chemical Trading (Pty) Ltd